Academic Journal
Enrolment of the first paediatric cohort into the Australian lupus registry and biobank: A single-centre experience
| Title: | Enrolment of the first paediatric cohort into the Australian lupus registry and biobank: A single-centre experience |
|---|---|
| Authors: | Bronwyn D Power, Rangi Kandane-Rathnayake, Georgina Tiller, William D Renton, Angela Cox, Lilian Johnstone, Alberta Hoi, Peter Gowdie |
| Source: | Lupus. 33:749-758 |
| Publisher Information: | SAGE Publications, 2024. |
| Publication Year: | 2024 |
| Subject Terms: | Male, Adolescent, Australia, Severity of Illness Index, 3. Good health, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Quality of Life, Humans, Lupus Erythematosus, Systemic, Feasibility Studies, Female, Registries, Patient Reported Outcome Measures, Child, Biological Specimen Banks |
| Description: | Introduction We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures. Methods All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified. Patients were enrolled in the ALRB if they met ≥4/11 of the American College of Rheumatology (ACR) 1997 SLE classification criteria or the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria. Enrolment data including demographics, clinical characteristics, serological profiles, disease activity and damage assessments were recorded. Peds-QL Rheumatology and General Modules were used to assess patient and parent-reported outcomes. Results Twenty-seven patients were eligible for inclusion, with 26 patients (96%) consenting for enrolment. Twenty-five patients (92%) consented for biobanking. Twenty patients (77%) were female. The median age at enrolment was 16 years (interquartile range (IQR) 13.7, 17.4). The median disease duration from diagnosis was 3.2 years (IQR 1.4, 5.3). Sixteen patients (62%) had synovitis, 16 (62%) had cutaneous involvement, 4 (15%) had serositis, 17 (65%) had haematological involvement and 7 (27%) had renal involvement at enrolment. Nineteen patients (73%) were prescribed at least two disease-modifying anti-rheumatic medications (DMARDs). Hydroxychloroquine ( n = 22, 85%) and mycophenolate mofetil ( n = 9, 35%) were the most commonly prescribed DMARDs. The median SLEDAI-2K score was 2 (IQR 2, 4). Six patients (23%) had active disease (SLEDAI-2K ≥6) at enrolment. Three patients (11.5%) had reported damage using the SLICC/ACR Damage Index. Twenty-three children (88%) and eighteen parents (69%) completed the Paediatric Quality of Life Inventory. Quality of life scores reported across domains of physical, emotional, social and school functioning at enrolment were comparable to previously studied paediatric cohorts with SLE and other chronic diseases. Conclusion We have established our centre as the first paediatric participating site of the ALRB, providing contemporary data on the clinical characteristics, serological profile and health-related quality of life outcomes of Australian children with SLE. Paediatric involvement with this national registry will provide a unique perspective for future clinical and scientific research. Collection of Australian-specific paediatric longitudinal data will also enable a broader understanding of SLE within a multicultural Australian population. |
| Document Type: | Article |
| Language: | English |
| ISSN: | 1477-0962 0961-2033 |
| DOI: | 10.1177/09612033241244879 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/38587355 |
| Rights: | URL: https://journals.sagepub.com/page/policies/text-and-data-mining-license |
| Accession Number: | edsair.doi.dedup.....a53b34c4e157f8ff1bae2d4bf10509c2 |
| Database: | OpenAIRE |
| ISSN: | 14770962 09612033 |
|---|---|
| DOI: | 10.1177/09612033241244879 |